AstraZeneca is to partner with an international not-for-profit organization in a corporation designed in such a way, so as to find new treatments for malaria.
The accord will see the pharmaceutical Company offer the Medicines for Malaria Venture by offering admission to its compound library so as to recognize potentially capable drugs.
This procedure will engage the screening of almost 500,000 compounds for treatments, which reveal efficiency against the lethal malaria parasite, P. falciparum, with the proposal intended to form the foundation of new anti-malarial drug discovery projects.
It is expected that schemes like this one will finally lead to the formation of a one-dose treatment for malaria, which is a disease that is becoming more and more hazardous because of the growth of drug-resistant strains.
David Brennan, AstraZeneca's Chief Executive Officer, said that the team’s experience with infection study, and certainly with all of the research and growth efforts, has been able to teach them that the solutions will be found to today's global health problems through joint efforts.
No comments:
Post a Comment